Transient deterioration of albumin–bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study

Real-world clinical cases of molecularly targeted agent (MTA) administration to patients with advanced hepatocellular carcinoma (HCC) with ≥50% liver occupation have been reported, but treatment outcomes have rarely been described. We have encountered several cases in which albumin–bilirubin (ALBI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Muto, Hisanori, Kuzuya, Teiji, Ito, Takanori, Ishizu, Yoji, Honda, Takashi, Ishikawa, Tetsuya, Ishigami, Masatoshi, Fujishiro, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341339/
https://www.ncbi.nlm.nih.gov/pubmed/34397843
http://dx.doi.org/10.1097/MD.0000000000026820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341339/
https://www.ncbi.nlm.nih.gov/pubmed/34397843
http://dx.doi.org/10.1097/MD.0000000000026820

Ejemplares similares